会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
    • 具有预水合膜和/或可引导导管的渗透泵输送系统
    • US06616652B1
    • 2003-09-09
    • US09504603
    • 2000-02-15
    • Derek J. HarperCharles F. Milo
    • Derek J. HarperCharles F. Milo
    • A61K922
    • A61K9/0004A61K9/0024
    • An implantable osmotic pump system includes a pre-hydrated semipermeable membrane to reduce the time interval between implantation of the system into the patient and full operation of the pump system. The semipermeable membrane is maintained in a hydrated state prior to implantation by fluid contact with a saline solution maintained in a saturated state by a salt tablet. As the differential osmotic pressure across the hydrated semipermeable membrane is negligible as the saline concentration on both sides of the membrane is the same, the pump system does not operate and does not infuse the pharmaceutical agent as long as this osmotic equipotential state is maintained. When the saturated saline solution is removed from fluid contact with the semipermeable membrane and the system is implanted in a patient, the osmotic pressure differential across the semipermeable membrane increases, thereby causing the pump to immediately begin operation at or near its intended and designed steady state infusion rate. To further decrease the delay between implantation and effusion of a pharmaceutical agent from the system, the infusion lumen of an attached catheter may be at least partially flushed with the same or a different pharmaceutical agent as is loaded in the pharmaceutical agent compartment of the pump system.
    • 可植入渗透泵系统包括预水合的半透膜,以减少将系统植入患者之间的时间间隔和泵系统的完全操作。 在通过与盐片保持在饱和状态的盐水溶液的液体接触之前,将半透膜保持在水合状态。 由于膜两侧的盐水浓度相同,水合半透膜两侧的差异渗透压可忽略不计,只要保持渗透等电位状态,泵系统就不会运行,也不会注入药剂。 当将饱和盐水溶液从与半透膜接触的液体中除去并将该系统植入患者体内时,半透膜上的渗透压差增加,从而使泵立即在其预期和设计的稳定状态或其附近开始操作 输液速度。 为了进一步减少来自系统的药剂的植入和渗出之间的延迟,附着的导管的输液腔可以用与泵系统的药剂隔室中所装载的相同或不同的药剂至少部分地冲洗 。
    • 3. 发明授权
    • Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
    • 用于长期递送药剂的方法和可植入装置和系统
    • US06436091B1
    • 2002-08-20
    • US09442128
    • 1999-11-16
    • Derek J. HarperCharles F. Milo
    • Derek J. HarperCharles F. Milo
    • A61K922
    • A61M31/002A61M2005/14513
    • Implantable devices and osmotic pump and catheter systems for delivering a pharmaceutical agent to a patient at selectable rates include an impermeable pump housing and a moveable partition disposed within the housing, the partition dividing the housing into an osmotic driving compartment having an open end and a pharmaceutical agent compartment having a delivery orifice. A plurality of semi permeable membranes may be disposed in the open end of the osmotic driving compartment and a number of impermeable barriers may seal selected ones of the plurality of semi permeable membranes from the patient until breached. Breaching one or more of the impermeable barriers increases the surface area of semi permeable membrane exposed to the patient and controllably increases the delivery rate of the pharmaceutical agent through the delivery orifice and catheter. Each of the plurality of semi permeable membranes may have a selected surface area, composition and/or thickness, to allow a fine-grained control over the infusion rate while the pump is implanted in the patient.
    • 用于以可选择的速率将药剂递送到患者的可植入装置和渗透泵和导管系统包括不可渗透的泵壳体和设置在所述壳体内的可移动隔板,所述隔板将所述壳体分成具有开口端的渗透驱动隔室和药物 药剂隔室具有输送口。 多个半透膜可以设置在渗透驱动室的开口端中,并且许多不渗透屏障可以将来自患者的多个半渗透膜中的选定的一个渗透膜密封,直到被破坏。 破坏一个或多个不渗透屏障增加暴露于患者的半渗透膜的表面积,并且可控地增加药剂通过输送孔和导管的输送速率。 多个半渗透膜中的每一个可以具有选择的表面积,组成和/或厚度,以允许在将泵植入患者体内时对输注速率进行细粒度控制。
    • 4. 发明授权
    • Osmotic pump drug delivery systems and methods
    • 渗透泵药物输送系统及方法
    • US06471688B1
    • 2002-10-29
    • US09503821
    • 2000-02-15
    • Derek J. HarperCharles F. Milo
    • Derek J. HarperCharles F. Milo
    • A61M3100
    • A61M5/14276A61M5/145A61M5/16827A61M2005/14513A61M2205/16
    • Implantable osmotic pump devices and systems include multiple osmotic pumps and/or semipermeable membranes to extend the useful life cycle and functionality of the drug delivery system. Use of an implantable system including multiple implantable osmotic pumps allows different drugs to be administered from the same implanted system. One or more of the semipermeable membranes of the system may be initially sealed by an overlying impermeable membrane upon implantation of the system into the patient. When the patient develops a tolerance to a first drug or to a first dose of the first drug, the impermeable membrane may be breached, to expose the underlying semipermeable membrane to the osmotic pressure of the patient at the implant site. This causes the infusion rate to increase, thereby providing the patient with the needed relief and/or other desired therapeutic effect. In the case of a multiple pump system, breaching an impermeable membrane may cause the infusion of a second drug. The second drug may potentiate a therapeutic effect (such as an analgesic effect) of the first drug, as is the case with Sufentanil and Clonidine.
    • 可植入的渗透泵装置和系统包括多个渗透泵和/或半透膜,以延长药物递送系统的使用寿命周期和功能。 使用包括多个可植入渗透泵的可植入系统允许从相同的植入系统施用不同的药物。 当系统植入患者体内时,系统的一个或多个半透膜最初可被上覆的不可渗透膜密封。 当患者对第一药物或第一剂量的第一药物产生耐受性时,可以破坏不渗透膜,以将下面的半透膜暴露于患者在植入部位的渗透压。 这导致输注速率增加,从而为患者提供所需的缓解和/或其他期望的治疗效果。 在多泵系统的情况下,突破不渗透膜可引起第二药物的输注。 第二种药物可以增强第一种药物的治疗效果(如止痛效果),就像苏芬太尼和可乐定一样。
    • 5. 发明授权
    • Osmotic pump delivery system with flexible drug compartment
    • 渗透泵输送系统具有灵活的药物隔室
    • US06464688B1
    • 2002-10-15
    • US09504971
    • 2000-02-15
    • Derek J. HarperCharles F. Milo
    • Derek J. HarperCharles F. Milo
    • A61M3100
    • A61M5/14276A61K9/0004A61M5/1483A61M2005/14513
    • An implantable osmotic pump system includes a rigid pump housing defining an opening adapted to receive a catheter; one or more membrane assemblies fitted to the pump housing; an osmotic engine within the rigid pump housing and a flexible pharmaceutical agent compartment disposed within the pump housing. The flexible pharmaceutical agent compartment is adapted to enclose a volume of a pharmaceutical agent and to cause the pharmaceutical agent to be infused through the opening as water crosses the membrane assembly or assemblies and increases the volume of the osmotic engine. The flexible pharmaceutical agent compartment may include polyethylene teraphthalate (PET), for example, and/or may include a metallic layer such as gold, silver, platinum and/or aluminum, for example, to inhibit the transfer of gas or liquid across the compartment. A catheter may be bonded to the opening of the pump housing and to a corresponding opening in the flexible pharmaceutical agent compartment. The flexible pharmaceutical agent compartment may be free floating inside the pump housing, being only attached to the catheter and/or to the opening of the pump housing. As the present implantable osmotic pump does not include a movable piston, the pump housing may have a cylindrical shape in which the height of the pump housing is less than the diameter thereof, a non-cylindrical shape and/or a shape that conforms to the patient's anatomy at the implant site.
    • 可植入渗透泵系统包括限定适于接收导管的开口的刚性泵壳体; 安装在泵壳体上的一个或多个膜组件; 刚性泵壳体内的渗透引擎和设置在泵壳体内的柔性药剂隔室。 柔性药剂隔室适于封闭一定体积的药剂,并且当水穿过膜组件或组件并增加渗透引擎的体积时,使药剂通过开口注入。 柔性药剂隔室可以包括例如聚对苯二甲酸乙二醇酯(PET)和/或可以包括例如金,银,铂和/或铝的金属层,以抑制气体或液体跨过隔室的转移 。 导管可以结合到泵壳体的开口和柔性药剂隔室中的相应开口。 柔性药剂隔室可以在泵壳体内自由浮动,仅附接到导管和/或连接到泵壳体的开口。 由于本植入式渗透泵不包括可移动活塞,所以泵壳体可以具有圆柱形形状,其中泵壳体的高度小于其直径,非圆柱形形状和/或符合 患者在植入部位的解剖结构。